8-K: Viskase Holdings Completes Merger, Rebrands

Enzon Pharmaceuticals, Inc. has completed its merger with Viskase Companies, Inc., rebranding as Viskase Holdings, Inc. and focusing on the combined entity's core business.

Summary

• Enzon Pharmaceuticals, Inc. (now Viskase Holdings, Inc.) completed its previously announced merger with Viskase Companies, Inc. on March 26, 2026.
• Viskase Companies, Inc. merged into a wholly-owned subsidiary of Enzon, subsequently converting into Viskase Companies, LLC.
• The combined company will operate under the new name Viskase Holdings, Inc.
• Affiliates of Icahn Enterprises Holdings L.P. (IEH) exchanged 39,277 shares of Series C Preferred Stock for 5,658,396 shares of Company Common Stock on March 25, 2026.
• Each share of Viskase Common Stock was converted into the right to receive 0.049118 shares of the Company Common Stock.
• Former Enzon stockholders will own approximately 45% of the combined company's common stock, while former Viskase stockholders will own approximately 55%.
• The Company Common Stock began trading on a reverse stock split-adjusted basis on the OTCQB under the temporary symbol ENZND for 20 trading days starting March 25, 2026.
• The company filed a Certificate of Amendment to change its name and a Certificate of Elimination for Series A-1 Junior Participating Preferred Stock, which had no outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the completion of a major strategic merger typically reduces uncertainty and allows the combined entity to move forward with its business objectives. The clear outline of new management and corporate structure provides stability.

Positives

• Completion of a strategic merger, forming Viskase Holdings, Inc., which reduces uncertainty.
• Consolidation of Viskase Companies, LLC's business under a publicly traded parent, potentially enhancing market position and access to capital.

Risks

• Anticipated benefits of the transaction, including revenues, expenses, earnings, financial results, growth, expansion, and tax treatment, may not be fully realized.
• Potential litigation related to the transaction could be instituted against the combined company, Viskase, or their respective officers or directors.
• Challenges in retaining, attracting, and hiring key personnel for the combined company.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties resulting from the completion of the transaction.
• Potential business uncertainty, including changes to existing business relationships, that could affect the combined company's financial performance.
• Unpredictability and severity of catastrophic events, such as acts of terrorism, trade wars, or outbreaks of war or hostilities, and management's response to such factors.
• Impact of legislative, regulatory, and economic developments on the combined company's operations and financial results.

Future Outlook

The combined company, Viskase Holdings, Inc., will focus on advancing Viskase Companies, LLC's business, which involves producing non-edible cellulosic, fibrous, and plastic casings used to prepare and package processed meat and poultry products, and providing value-added product support services to its customers.

Management Comments

• Enzon Pharmaceuticals, Inc. announced the completion of the previously announced merger pursuant to which Viskase Companies, Inc. merged with and into a wholly owned subsidiary of Enzon in an all-stock transaction.

Industry Context

StockSavvy.ai notes that this merger creates a publicly traded entity focused on the specialized food packaging industry, specifically non-edible casings for meat and poultry. This consolidation could enhance Viskase's market position and access to capital, potentially impacting competitors in the food processing and packaging sector by creating a larger, more integrated player.

Comparison to Industry Standards

• This filing primarily concerns a merger completion and corporate restructuring rather than operational results. Therefore, a direct comparison to industry-specific financial benchmarks or competitor project results is not applicable.
• The ownership split (45% for former Enzon, 55% for former Viskase) reflects the agreed-upon valuation and contribution of each entity to the combined company.

Management Changes

Corporate Governance

Related Party Transactions

• 5,658,396 shares of the Company Common Stock were issued to affiliates of Icahn Enterprises Holdings L.P. (IEH) in exchange for 39,277 shares of Series C Preferred Stock previously held by affiliates of IEH.

Stakeholder Impact

• Shareholders (former Enzon): Now own approximately 45% of Viskase Holdings, Inc., with their stock trading under a new temporary symbol and adjusted for a reverse stock split.
• Shareholders (former Viskase): Now own approximately 55% of Viskase Holdings, Inc., receiving 0.049118 shares of Company Common Stock for each Viskase Common Stock share.
• Employees (Viskase): Officers of Viskase immediately prior to the closing became officers of the Combined Company, suggesting continuity for key personnel.
• Customers/Suppliers: The combined company will continue to focus on Viskase's business, potentially leading to enhanced product offerings or stability.

Next Steps

• The Company Common Stock will trade under the temporary symbol ENZND for 20 trading days.
• Financial statements of the acquired business and pro forma financial information will be filed by amendment within 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed.

Key Dates

Recommendation

The filing details the completion of a previously announced merger and significant corporate restructuring, including a name change and management overhaul. While the completion of the merger removes uncertainty, the immediate financial impact and future performance of the combined entity are yet to be fully realized. The company will focus on Viskase's business, which is a positive, but the market will need to assess the integration and execution under the new leadership. The temporary trading symbol and upcoming financial filings suggest a period of transition. A 'hold' recommendation allows investors to observe the initial performance and strategic direction of the newly formed Viskase Holdings, Inc. before making further investment decisions.

Keywords

Viskase Holdings, Enzon Pharmaceuticals, Merger, Acquisition, Corporate Governance, SEC Filing, 8-K, Stock Split, Name Change, Preferred Stock Exchange, OTC Markets, Meat Casings, Food Packaging